GENMAB A/S (GE9.DE) Fundamental Analysis & Valuation

FRA:GE9 • DK0010272202

Current stock price

229.8 EUR
+3 (+1.32%)
Last:

This GE9.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GE9.DE Profitability Analysis

1.1 Basic Checks

  • In the past year GE9 was profitable.
  • In the past year GE9 had a positive cash flow from operations.
  • Each year in the past 5 years GE9 has been profitable.
  • Each year in the past 5 years GE9 had a positive operating cash flow.
GE9.DE Yearly Net Income VS EBIT VS OCF VS FCFGE9.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • GE9 has a better Return On Assets (7.48%) than 81.25% of its industry peers.
  • With an excellent Return On Equity value of 16.47%, GE9 belongs to the best of the industry, outperforming 88.75% of the companies in the same industry.
  • The Return On Invested Capital of GE9 (9.04%) is better than 82.50% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GE9 is in line with the industry average of 11.89%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GE9.DE Yearly ROA, ROE, ROICGE9.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 25.89%, GE9 belongs to the best of the industry, outperforming 83.75% of the companies in the same industry.
  • GE9's Profit Margin has declined in the last couple of years.
  • The Operating Margin of GE9 (33.60%) is better than 87.50% of its industry peers.
  • In the last couple of years the Operating Margin of GE9 has declined.
  • GE9 has a better Gross Margin (93.60%) than 85.00% of its industry peers.
  • In the last couple of years the Gross Margin of GE9 has declined.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GE9.DE Yearly Profit, Operating, Gross MarginsGE9.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GE9.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GE9 is creating some value.
  • Compared to 1 year ago, GE9 has less shares outstanding
  • The number of shares outstanding for GE9 has been reduced compared to 5 years ago.
  • GE9 has a worse debt/assets ratio than last year.
GE9.DE Yearly Shares OutstandingGE9.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
GE9.DE Yearly Total Debt VS Total AssetsGE9.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • GE9 has an Altman-Z score of 14.89. This indicates that GE9 is financially healthy and has little risk of bankruptcy at the moment.
  • GE9 has a Altman-Z score of 14.89. This is amongst the best in the industry. GE9 outperforms 95.00% of its industry peers.
  • The Debt to FCF ratio of GE9 is 4.80, which is a neutral value as it means it would take GE9, 4.80 years of fcf income to pay off all of its debts.
  • GE9 has a Debt to FCF ratio of 4.80. This is amongst the best in the industry. GE9 outperforms 82.50% of its industry peers.
  • A Debt/Equity ratio of 0.88 indicates that GE9 is somewhat dependend on debt financing.
  • GE9 has a Debt to Equity ratio of 0.88. This is comparable to the rest of the industry: GE9 outperforms 48.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 14.89
ROIC/WACC1.27
WACC7.14%
GE9.DE Yearly LT Debt VS Equity VS FCFGE9.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • GE9 has a Current Ratio of 2.02. This indicates that GE9 is financially healthy and has no problem in meeting its short term obligations.
  • GE9 has a Current ratio (2.02) which is in line with its industry peers.
  • GE9 has a Quick Ratio of 2.01. This indicates that GE9 is financially healthy and has no problem in meeting its short term obligations.
  • GE9 has a Quick ratio of 2.01. This is comparable to the rest of the industry: GE9 outperforms 47.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GE9.DE Yearly Current Assets VS Current LiabilitesGE9.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GE9.DE Growth Analysis

3.1 Past

  • GE9 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.61%.
  • Measured over the past years, GE9 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.47% on average per year.
  • Looking at the last year, GE9 shows a quite strong growth in Revenue. The Revenue has grown by 19.25% in the last year.
  • Measured over the past years, GE9 shows a quite strong growth in Revenue. The Revenue has been growing by 19.19% on average per year.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.91%

3.2 Future

  • GE9 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.88% yearly.
  • GE9 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.86% yearly.
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GE9.DE Yearly Revenue VS EstimatesGE9.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GE9.DE Yearly EPS VS EstimatesGE9.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

5

4. GE9.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 15.46, GE9 is valued correctly.
  • 92.50% of the companies in the same industry are more expensive than GE9, based on the Price/Earnings ratio.
  • GE9 is valuated rather cheaply when we compare the Price/Earnings ratio to 25.35, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 18.21, which indicates a rather expensive current valuation of GE9.
  • Based on the Price/Forward Earnings ratio, GE9 is valued cheaply inside the industry as 85.00% of the companies are valued more expensively.
  • GE9 is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.61, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.46
Fwd PE 18.21
GE9.DE Price Earnings VS Forward Price EarningsGE9.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GE9 is valued a bit cheaper than 73.75% of the companies in the same industry.
  • GE9's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. GE9 is cheaper than 78.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 143.67
EV/EBITDA 124.21
GE9.DE Per share dataGE9.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • The decent profitability rating of GE9 may justify a higher PE ratio.
  • A more expensive valuation may be justified as GE9's earnings are expected to grow with 17.95% in the coming years.
PEG (NY)N/A
PEG (5Y)1.63
EPS Next 2Y5.16%
EPS Next 3Y17.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GE9.DE Dividend Analysis

5.1 Amount

  • GE9 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GE9.DE Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S

FRA:GE9 (3/31/2026, 7:00:00 PM)

229.8

+3 (+1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners42.45%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap141.49B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts73.85
Price Target307.95 (34.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)5
Avg Revenue beat(8)0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.57%
Revenue beat(16)10
Avg Revenue beat(16)2.35%
PT rev (1m)0%
PT rev (3m)7.06%
EPS NQ rev (1m)-27.73%
EPS NQ rev (3m)-52.45%
EPS NY rev (1m)-14.23%
EPS NY rev (3m)-17.2%
Revenue NQ rev (1m)-1.13%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)1.95%
Revenue NY rev (3m)0.81%
Valuation
Industry RankSector Rank
PE 15.46
Fwd PE 18.21
P/S 43.68
P/FCF 143.67
P/OCF 137.01
P/B 27.79
P/tB N/A
EV/EBITDA 124.21
EPS(TTM)14.86
EY6.47%
EPS(NY)12.62
Fwd EY5.49%
FCF(TTM)1.6
FCFY0.7%
OCF(TTM)1.68
OCFY0.73%
SpS5.26
BVpS8.27
TBVpS-5.14
PEG (NY)N/A
PEG (5Y)1.63
Graham Number52.58
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 14.89
F-Score4
WACC7.14%
ROIC/WACC1.27
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.91%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-1.15%
EBIT Next 3Y19.58%
EBIT Next 5Y4.81%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S / GE9.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GENMAB A/S?

ChartMill assigns a fundamental rating of 6 / 10 to GE9.DE.


Can you provide the valuation status for GENMAB A/S?

ChartMill assigns a valuation rating of 5 / 10 to GENMAB A/S (GE9.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S?

GENMAB A/S (GE9.DE) has a profitability rating of 7 / 10.


What is the financial health of GENMAB A/S (GE9.DE) stock?

The financial health rating of GENMAB A/S (GE9.DE) is 7 / 10.